Payment overview · 2025
General Payments
$581.62
27 reported records · 12 companies
Healthcare provider profile · identity verified
Heena M Contractor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LOS ALAMITOS, CA · NPI 1518954973
Verified facts
What the public records show
CMS Open Payments records show Heena M Contractor, M.D. received $581.62 in general payments during 2025 across 27 reported records.
Ardelyx, Inc. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $145.43 | 25.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.75 | 10.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.81 | 9.2% | 2 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $53.32 | 9.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.23 | 9.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.11 | 8.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.09 | 7.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.62 | 5.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.29 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.92 | 4.5% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.75 | 4.1% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.30 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $581.62 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $145.43 | 9 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $62.75 | 3 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $53.81 | 2 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $53.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.23 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $43.09 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $23.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 61 |
| Eliquis | Apixaban | 234 | 37 |
| Furosemide | Furosemide | 178 | 41 |
| Losartan Potassium | Losartan Potassium | 175 | 48 |
| Gabapentin | Gabapentin | 143 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 27 |
| Allopurinol | Allopurinol | 90 | 21 |
| Lisinopril | Lisinopril | 87 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 23 |
| Donepezil Hcl | Donepezil Hcl | 86 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 24 |
| Famotidine | Famotidine | 85 | 20 |
| Carvedilol | Carvedilol | 84 | 26 |
| Memantine Hcl | Memantine Hcl | 78 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 26 |
| Calcitriol | Calcitriol | 62 | 13 |
| Lidocaine | Lidocaine | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Finasteride | Finasteride | 61 | 11 |
| Metformin Hcl | Metformin Hcl | 61 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 19 |
| Latanoprost | Latanoprost | 60 | suppressed |
| Prednisone | Prednisone | 55 | 18 |
| Clonidine Hcl | Clonidine Hcl | 53 | 16 |
| Lorazepam | Lorazepam | 53 | 11 |
| Omeprazole | Omeprazole | 53 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 15 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Sevelamer Hcl | Sevelamer Hcl | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | 18 |
| Humulin R | Insulin Regular, Human | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Azithromycin | Azithromycin | 33 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Calcium Acetate | Calcium Acetate | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 21 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Xphozah | Tenapanor Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Acetylcysteine | Acetylcysteine | 11 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lovastatin | Lovastatin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $581.62 · 27 records | Ardelyx, Inc. | FARXIGA, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, RAYALDEE, REXULTI, ULTOMIRIS, Vafseo | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error